New Brunswick Scientific Co., Inc. (NBSC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : New Brunswick Scientific Co., Inc. (NBSC)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who started this subject	9/8/2000 1:37:08 PM
From: scaram(o)uche	Read Replies (1) of 724

Cool! Here's solid evidence of continued progress at DGI..... WO047611A2: POLYMERIC IMMUNOGLOBULIN RECEPTOR (PIGR)-BINDING DOMAINS AND METHODS OF USE THEREFOR patent.womplex.ibm.com Filed 2/11/00. One of the inventors is Don Capra, who I have tremendous respect for. The present invention identifies a domain located in the C.agr.3 domain of IgA that is reponsible for targeting of the polymeric immunoglobulin receptor (pIgR) and transport of the antibody to the mucosal epithelium. This pIgR-binding domain may be used to target a wide variety of compositions, including proteins, nucleic acids, drugs and diagnositic agents, to the mucosal surface. Other more specific targeting agents may be used in conjunction with the pIgR-binding domain to define further the ultimate localization of the complexes in the body. Treatment of a large number of disease conditions such as viral, fungal and bacterial infections, as well as cancer, may be improved through the use of a pIgR-binding domain.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next